Eli Lilly & Co. (LLY) Misses Q3 EPS by 7c

Eli Lilly & Co. (NYSE: LLY) reported Q3 EPS of $0.88, $0.07 worse than the analyst estimate of $0.95. Revenue for the quarter came in at $5.19 billion versus the consensus estimate of $5.29 billion.

Cialis revenue was $588.2 million. Est. at $594.7 million

Alinta revenue was $570.4 million, est at $551.7 million.

Eli Lilly & Co. reaffirmed FY2016 guidance.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 21c
• Southland Holdings (SLND) Misses Q2 EPS by 122c